Edema

• CLINICAL_TRIALS trial_result · 2025-04-11
  Clinical Trial Update: Fluidotherapy in Patients With Distal Radius Fractures [NA]

  A clinical trial evaluating fluidotherapy for distal radius fractures has completed.

• FDA approval · 2025-04-03
  FDA Approved: BUMETANIDE — Original Application (First Nation Group, LLC)

  FDA approves bumetanide under an Original Application filed by First Nation Group, LLC (ANDA219291).

• CLINICAL_TRIALS trial_result · 2025-04-02
  Clinical Trial Update: Effect of Body Weight Loading on Urinary Electrolyte Excretion [NA]

  A completed clinical trial from Göteborg University examining whether body weight loading influences urinary electrolyte excretion in indivi…

• FDA approval · 2025-03-17
  FDA Approved: HEMICLOR — Original Application (Ingenus Pharmaceuticals, LLC)

  FDA approves HemiclOR (chlorthalidone) through an Original Application by Ingenus Pharmaceuticals, LLC.

• FDA approval · 2025-03-12
  FDA Approved: ACETAZOLAMIDE — Supplemental Application (Ajanta Pharma USA Inc.)

  FDA approved a supplemental application for acetazolamide submitted by Ajanta Pharma USA Inc.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS research · 2025-03-11
  Clinical Trial Update: Surgical Evaluation for Upper Extremity Lymphedema (BioBridge) [NA]

  Clinical trial update for BioBridge surgical evaluation of upper extremity lymphedema, sponsored by Fibralign Corporation, currently recruit…

• CLINICAL_TRIALS trial_result · 2025-02-26
  Clinical Trial Update: MOdification of Fluid Distribution in 90 Minutes [NA]

  A clinical trial (NCT05786248) sponsored by Poitiers University Hospital focusing on Obstructive Sleep Apnea and edema has completed; the st…

• FDA approval · 2025-01-28
  FDA Approved: INZIRQO — Original Application (ANI Pharmaceuticals, Inc.)

  FDA approved INZIRQO, a brand-name hydrochlorothiazide, under ANI Pharmaceuticals' original application.

• FDA approval · 2025-01-28
  FDA Approved: TRIAMTERENE AND HYDROCHLOROTHIAZIDE — Original Application (Macleods Pharmaceuticals Limited)

  FDA approved a generic fixed-dose combination of tri­amterene and hydrochlorothiazide from Macleods Pharmaceuticals Limited under an origina…

• FDA approval · 2025-01-23
  FDA Approved: SPIRONOLACTONE — Original Application (Rising Pharma Holdings, Inc.)

  The FDA approved the original application for spironolactone (generic) from Rising Pharma Holdings, Inc., authorizing the marketing of a gen…

• FDA approval · 2024-12-12
  FDA Approved: ACETAZOLAMIDE — Supplemental Application (Alembic Pharmaceuticals Inc.)

  FDA approved a supplemental application for Acetazolamide from Alembic Pharmaceuticals Inc., indicating a supplemental approval for this gen…

• CLINICAL_TRIALS research · 2024-11-20
  Clinical Trial Update: Muscle and Subcutaneous Tissue Variation by Ultrasound and Impedance Linked to Fluid Balance in ICU Patients

  This clinical trial update indicates ongoing recruitment for a study evaluating muscle and subcutaneous tissue variation via ultrasound and …

• FDA approval · 2024-10-01
  FDA Approved: FUROSEMIDE — Supplemental Application (Phlow Corporation)

  The FDA approved a supplemental application for furosemide from Phlow Corporation, authorizing an additional or revised approval for the diu…

• FDA approval · 2024-09-19
  FDA Approved: HYDROCHLOROTHIAZIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

  FDA approved a supplemental application for hydrochlorothiazide from Teva Pharmaceuticals USA, Inc. The approval concerns regulatory changes…

• FDA approval · 2024-09-19
  FDA Approved: BUMETANIDE — Original Application (Qilu Pharmaceutical Co., Ltd.)

  FDA approved bumetanide (Original Application) by Qilu Pharmaceutical as a generic diuretic for edema associated with congestive heart failu…

• FDA approval · 2024-08-23
  FDA Approved: INDAPAMIDE — Supplemental Application (Rising Pharma Holdings, Inc.)

  The FDA approved a supplemental application for Indapamide submitted by Rising Pharma Holdings, Inc., under the ANDA.

• FDA approval · 2024-05-15
  FDA Approved: ACETAZOLAMIDE — Supplemental Application (Lifestar Pharma LLC)

  FDA has approved a supplemental application for acetazolamide submitted by Lifestar Pharma LLC.

• CLINICAL_TRIALS trial_result · 2024-05-08
  Clinical Trial Update: Weightlessness Associated Cephalad Fluid Shifts; The Potential to Evaluate Venous and Lymphatic Dysfunction

  This clinical trial update reports on a completed study examining weightlessness-related cephalad fluid shifts and the potential to evaluate…

• CLINICAL_TRIALS trial_result · 2024-05-08
  Clinical Trial Update: Soft Part Management for Surgical Fractures of the Lower Limb [NA]

  This ClinicalTrials.gov update reports the completion of a study on soft tissue management for surgical fractures of the lower limb. The lis…

• FDA approval · 2024-04-30
  FDA Approved: HYDROCHLOROTHIAZIDE — Supplemental Application (Accord Healthcare Inc.)

  The FDA approved a supplemental application for hydrochlorothiazide filed by Accord Healthcare Inc. under ANDA 202556. The document does not…

• FDA approval · 2024-04-30
  FDA Approved: HYDROCHLOROTHIAZIDE — Supplemental Application (ScieGen Pharmaceuticals Inc)

  The FDA approved a supplemental application for hydrochlorothiazide submitted by ScieGen Pharmaceuticals Inc., endorsing changes to the prod…

• FDA approval · 2024-04-04
  FDA Approved: HYDROCHLOROTHIAZIDE — Supplemental Application (Aurobindo Pharma Limited)

  FDA approved a supplemental application for Hydrochlorothiazide from Aurobindo Pharma Limited (generic).

• FDA approval · 2024-04-02
  FDA Approved: FUROSEMIDE — Original Application (Devatis Inc.)

  FDA approved Devatis Inc.'s original application for a generic furosemide product, enabling its marketing in the United States.

• CLINICAL_TRIALS trial_result · 2024-03-25
  Clinical Trial Update: Furosemide and Albumin for Diuresis of Edema: A Pilot Randomized Controlled Trial [Phase 3]

  A Phase 3 pilot randomized trial evaluating furosemide with albumin for diuresis in edema related to hypoproteinemia has completed, with res…

• FDA approval · 2024-03-21
  FDA Approved: HYDROCHLOROTHIAZIDE — Supplemental Application (Alembic Pharmaceuticals Limited)

  FDA approves a supplemental application for Hydrochlorothiazide from Alembic Pharmaceuticals Limited.